Abstract
ADAW asked representatives of the press offices of the Substance Abuse and Mental Health Services Administration and its parent agency, the Department of Health and Human Services, to respond to our question: Why did they weaken the privacy and not strengthen the anti‐discrimination provisions of 42 CFR Part 2 in their final rule issued last month? Congress required this to be done in the 2020 CARES Act. Neither office responded to our question. ADAW asked again this week, as promised. Still no response. We will continue to push for an answer. This time, we're also asking what they're going to do about it. Patients lose confidentiality for the rest of their lives with the first consent to release substance use disorder treatment information. And it can go to anyone, anywhere, anytime if they do consent. It's not only patients who don't like this; treatment providers don't either, because patients aren't going to want to go to treatment if this will happen. Still no response.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
